The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Use of an in-silico clinical trial intelligence solution to predict outcomes of tinengotinib, a potent multi-kinase small molecule FGFR inhibitor in patients with cholangiocarcinoma, based on the molecular matching score.
 
Ally Perlina
No Relationships to Disclose
 
Milind Javle
Honoraria - AstraZeneca/MedImmune; EMD Serono/Merck; Incyte; Merck; QED Therapeutics; TransThera Biosciences
Consulting or Advisory Role - AstraZeneca; Basilea Pharmaceutical; EMD Serono; incyte; Merck; Mundipharma; oncosil; QED Therapeutics
Other Relationship - Bayer; BeiGene; Incyte; Merck; Merck Serono; Novartis; Pieris Pharmaceuticals; QED Therapeutics; Rafael Pharmaceuticals; Seagen
 
Subha Krishnan
No Relationships to Disclose
 
Katie Hennessy
Employment - TransThera Biosciences
Travel, Accommodations, Expenses - TransThera Biosciences
 
Hui Wang
No Relationships to Disclose
 
Caixia Sun
No Relationships to Disclose
 
Peng Peng
Employment - TransThera Sciences (Nanjing), Inc.
Stock and Other Ownership Interests - TransThera Sciences (Nanjing), Inc.
Patents, Royalties, Other Intellectual Property - PCT/CN2022/091924 (Inst)
 
Navid Alipour
No Relationships to Disclose
 
Wael Harb
Employment - Syneos Health
Consulting or Advisory Role - CureMatch
 
Jean Fan
Employment - TransThera Biosciences
Leadership - TransThera Biosciences
Stock and Other Ownership Interests - AstraZeneca
 
Razelle Kurzrock
Leadership - CureMatch; CureMetrix; XZOM
Stock and Other Ownership Interests - CureMatch; CureMetrix; IDbyDNA
Honoraria - AACR; Bicara Therapeutics; Biocom; Chugai Pharma USA; EUSA Pharma; Foundation Medicine; LEK; Merck; NeoGenomics Laboratories; NeoMed; Pfizer; Roche; Turning Point Therapeutics; Wiley
Consulting or Advisory Role - Actuate Therapeutics; AstraZeneca; Bicara Therapeutics; Biological Dynamics; Caris Life Sciences; Daiichi Sankyo; Datar Genomics; Eisai; EMD Serono; EOM Pharmaceuticals; Gaido; Iylon; Jackson Laboratory for Genomic Medicine; LabCorp; Lanauria Therapeutics; Loxo; Merck; NeoGenomics Laboratories; NeoMed; Pfizer; Precirix; Precirix; Prosperdtx; Quanta Therapeutics; Recordati; Regeneron; Roche; Soluventis; TD2/Volastra; Turning Point Therapeutics; XBiotech
Speakers' Bureau - NeoGenomics Laboratories; Roche
Research Funding - Biological Dynamics (Inst); Boehringer Ingelheim (Inst); Debiopharm Group (Inst); Foundation Medicine (Inst); Genentech (Inst); Grifols (Inst); Guardant Health (Inst); Incyte (Inst); Konica Minolta (Inst); MedImmune (Inst); Merck Serono (Inst); NCI (Inst); OmniSeq (Inst); Pfizer (Inst); Sequenom (Inst); Sysmex (Inst); Takeda (Inst); Top Alliance BioScience (Inst)
Travel, Accommodations, Expenses - NCI SWOG; TargetCancer Foundation